NeuroBo backs onto Nasdaq via merger with Gemphire

Nasdaq
NeuroBo raised a $24.2 million series B round in conjunction with the reverse merger with Gemphire Therapeutics. (Nasdaq)

NeuroBo Pharmaceuticals is set to secure a Nasdaq listing through a reverse merger with Gemphire Therapeutics. The move comes as NeuroBo gears up to start a phase 3 trial of nerve growth factor (NGF) therapy NB-01 in patients with diabetic neuropathic pain.

Gemphire has been on the ropes since long-standing concerns about the safety of gemcabene were exacerbated by the discovery of liver tumors in animals treated with the drug, leading the FDA to ask the biotech to conduct additional studies before entering phase 3. In the wake of the news, Gemphire cut its headcount and began looking into strategic alternatives.

Management settled on a merger with NeuroBo as the best of the available alternatives. The deal will see NeuroBo subsume Gemphire. Investors in NeuroBo will own 96% of the combined company. 

Featured Webinar

From Concept to Market: Overcoming the Challenges of Manufacturing and Clinical Trials

In this webinar we will reveal the inner workings of the manufacturing and pharmacy department of a CRO/CDMO, so you understand the different regulatory and operational considerations faced by a clinical research pharmacy.

Learn how CRO/CDMOs successfully address operational and regulatory challenges for pharmaceutical and biotechnology clients; and how this can make the difference between study success or failure.

The split reflects the balance of power. The combined company will take NeuroBo’s name and focus on advancing its lead asset, NB-01. NeuroBo will gain rights to gemcabene but has committed to put just $1 million into its development through the end of March. If the drug makes any money in the coming years, 80% of the net proceeds will go to current Gemphire shareholders. 

While NeuroBo will put most of its money into its existing programs, Beijing SL Pharmaceutical could give gemcabene a new lease of life. The company paid Gemphire $2.5 million for the Chinese rights to the drug in a deal that features up to $6 million in development and regulatory milestones.

Gemphire CEO Steve Gullans thinks the combined investments of NeuroBo and Beijing SL could get the program out if its current predicament. 

“Together, these relationships will enable us to continue to advance gemcabene toward a FDA partial clinical hold decision and potentially lead to a beneficial outcome for Gemphire shareholders,” Gullans said in a statement. 

The fate of NeuroBo will be more closely tied to that of NB-01, though. NeuroBo plans to start a phase 3 trial of the NGF therapy in the fourth quarter using the proceeds from a $24.2 million series B round executed in conjunction with the merger. The amount raised to date is the minimum required under the terms of the merger agreement. 

Suggested Articles

Xevinapant in combination with standard cisplatin-based chemoradiation therapy (CRT) reduces the risk of death in high-risk patients with locally adva

The agency also gave the company’s diagnostic, run on the high-throughput Panther Fusion laboratory platform, a green light for pooled testing.

Smith & Nephew has signed up to acquire Integra LifeSciences’ orthopedics business focused on the growing upper and lower extremity markets.